Insulin Receptor Alternative Splicing in Breast and Prostate Cancer

Overview

Journal Cancer Cell Int

Publisher Biomed Central

Date 2024 Feb 8

PMID 38331804

Authors

Jinyu Li

Gena Huang

Affiliations

Soon will be listed here.

Abstract

Cancer etiology represents an intricate, multifactorial orchestration where metabolically associated insulin-like growth factors (IGFs) and insulin foster cellular proliferation and growth throughout tumorigenesis. The insulin receptor (IR) exhibits two splice variants arising from alternative mRNA processing, namely IR-A, and IR-B, with remarkable distribution and biological effects disparities. This insightful review elucidates the structural intricacies, widespread distribution, and functional significance of IR-A and IR-B. Additionally, it explores the regulatory mechanisms governing alternative splicing processes, intricate signal transduction pathways, and the intricate association linking IR-A and IR-B splicing variants to breast and prostate cancer tumorigenesis. Breast cancer and prostate cancer are the most common malignant tumors with the highest incidence rates among women and men, respectively. These findings provide a promising theoretical framework for advancing preventive strategies, diagnostic modalities, and therapeutic interventions targeting breast and prostate cancer.

Citing Articles

Unraveling the Role of Cathepsin B Variants in Polycystic Ovary Syndrome: Insights from a Case-Control Study and Computational Analyses.

Akbar-Abad M, Majidpour M, Sargazi S, Ghasemi M, Saravani R Reprod Sci. 2025; .

PMID: 40044993 DOI: 10.1007/s43032-025-01806-w.

Decoding the Role of Insulin-like Growth Factor 1 and Its Isoforms in Breast Cancer.

Kotsifaki A, Maroulaki S, Karalexis E, Stathaki M, Armakolas A Int J Mol Sci. 2024; 25(17).

PMID: 39273251 PMC: 11394947. DOI: 10.3390/ijms25179302.

Neoantigens in cancer immunotherapy: focusing on alternative splicing.

Huang P, Wen F, Tuerhong N, Yang Y, Li Q Front Immunol. 2024; 15:1437774.

PMID: 39055714 PMC: 11269099. DOI: 10.3389/fimmu.2024.1437774.

References

Ullrich A, Bell J, Chen E, Herrera R, Petruzzelli L, Dull T . Human insulin receptor and its relationship to the tyrosine kinase family of oncogenes. Nature. 1985; 313(6005):756-61. DOI: 10.1038/313756a0. View

White M . IRS proteins and the common path to diabetes. Am J Physiol Endocrinol Metab. 2002; 283(3):E413-22. DOI: 10.1152/ajpendo.00514.2001. View

Perks C, Zielinska H, Wang J, Jarrett C, Frankow A, Ladomery M . Insulin Receptor Isoform Variations in Prostate Cancer Cells. Front Endocrinol (Lausanne). 2016; 7:132. PMC: 5039983. DOI: 10.3389/fendo.2016.00132. View

Cohen P . The twentieth century struggle to decipher insulin signalling. Nat Rev Mol Cell Biol. 2006; 7(11):867-73. DOI: 10.1038/nrm2043. View

Heidegger I, Kern J, Ofer P, Klocker H, Massoner P . Oncogenic functions of IGF1R and INSR in prostate cancer include enhanced tumor growth, cell migration and angiogenesis. Oncotarget. 2014; 5(9):2723-35. PMC: 4058040. DOI: 10.18632/oncotarget.1884. View

Chiu S, Cline H . Insulin receptor signaling in the development of neuronal structure and function. Neural Dev. 2010; 5:7. PMC: 2843688. DOI: 10.1186/1749-8104-5-7. View

Malaguarnera R, Sacco A, Voci C, Pandini G, Vigneri R, Belfiore A . Proinsulin binds with high affinity the insulin receptor isoform A and predominantly activates the mitogenic pathway. Endocrinology. 2012; 153(5):2152-63. DOI: 10.1210/en.2011-1843. View

Huang G, Song C, Wang N, Qin T, Sui S, Obr A . RNA-binding protein CUGBP1 controls the differential INSR splicing in molecular subtypes of breast cancer cells and affects cell aggressiveness. Carcinogenesis. 2020; 41(9):1294-1305. PMC: 7513956. DOI: 10.1093/carcin/bgz141. View

Savkur R, Philips A, Cooper T . Aberrant regulation of insulin receptor alternative splicing is associated with insulin resistance in myotonic dystrophy. Nat Genet. 2001; 29(1):40-7. DOI: 10.1038/ng704. View

10.

Norgren S, Zierath J, Wedell A, Wallberg-Henriksson H, Luthman H . Regulation of human insulin receptor RNA splicing in vivo. Proc Natl Acad Sci U S A. 1994; 91(4):1465-9. PMC: 43180. DOI: 10.1073/pnas.91.4.1465. View

11.

Heidegger I, Ofer P, Doppler W, Rotter V, Klocker H, Massoner P . Diverse functions of IGF/insulin signaling in malignant and noncancerous prostate cells: proliferation in cancer cells and differentiation in noncancerous cells. Endocrinology. 2012; 153(10):4633-43. DOI: 10.1210/en.2012-1348. View

12.

Yamaguchi Y, Flier J, Benecke H, Ransil B, Moller D . Ligand-binding properties of the two isoforms of the human insulin receptor. Endocrinology. 1993; 132(3):1132-8. DOI: 10.1210/endo.132.3.8440175. View

13.

Slaaby R, Schaffer L, Lautrup-Larsen I, Andersen A, Shaw A, Mathiasen I . Hybrid receptors formed by insulin receptor (IR) and insulin-like growth factor I receptor (IGF-IR) have low insulin and high IGF-1 affinity irrespective of the IR splice variant. J Biol Chem. 2006; 281(36):25869-74. DOI: 10.1074/jbc.M605189200. View

14.

Saltiel A, Kahn C . Insulin signalling and the regulation of glucose and lipid metabolism. Nature. 2001; 414(6865):799-806. DOI: 10.1038/414799a. View

15.

Scotlandi K, Belfiore A . Targeting the Insulin-Like Growth Factor (IGF) System Is Not as Simple as Just Targeting the Type 1 IGF Receptor. Am Soc Clin Oncol Educ Book. 2014; :599-604. DOI: 10.14694/EdBook_AM.2012.32.134. View

16.

Geuens T, Bouhy D, Timmerman V . The hnRNP family: insights into their role in health and disease. Hum Genet. 2016; 135(8):851-67. PMC: 4947485. DOI: 10.1007/s00439-016-1683-5. View

17.

Wang X, Wang Y, Lan H, Li J . MiR-195 inhibits the growth and metastasis of NSCLC cells by targeting IGF1R. Tumour Biol. 2014; 35(9):8765-70. DOI: 10.1007/s13277-014-2140-5. View

18.

Malaguarnera R, Gabriele C, Santamaria G, Giuliano M, Vella V, Massimino M . Comparative proteomic analysis of insulin receptor isoform A and B signaling. Mol Cell Endocrinol. 2022; 557:111739. DOI: 10.1016/j.mce.2022.111739. View

19.

Haluska P, Menefee M, Plimack E, Rosenberg J, Northfelt D, LaVallee T . Phase I dose-escalation study of MEDI-573, a bispecific, antiligand monoclonal antibody against IGFI and IGFII, in patients with advanced solid tumors. Clin Cancer Res. 2014; 20(18):4747-57. PMC: 4377301. DOI: 10.1158/1078-0432.CCR-14-0114. View

20.

Yamaguchi Y, Flier J, Yokota A, Benecke H, Backer J, Moller D . Functional properties of two naturally occurring isoforms of the human insulin receptor in Chinese hamster ovary cells. Endocrinology. 1991; 129(4):2058-66. DOI: 10.1210/endo-129-4-2058. View